Vical Inc (VICL)

2.43
0.02 0.82
NASDAQ : Health Care
Prev Close 2.45
Open 2.44
Day Low/High 2.38 / 2.44
52 Wk Low/High 2.81 / 6.80
Volume 18.91K
Avg Volume 57.10K
Exchange NASDAQ
Shares Outstanding 11.40M
Market Cap 27.02M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Vical Reports First Quarter 2017 Financial Results

VL-2397 Data to be presented at ASM Microbe 2017 Conference in June

Vical's Phase 1/2 Trial Data Presented At ASM 2016 Shows Bivalent Vaccine Imparts Reduction In Genital Herpes Lesions Durable To 9 Months

Vical's Phase 1/2 Trial Data Presented At ASM 2016 Shows Bivalent Vaccine Imparts Reduction In Genital Herpes Lesions Durable To 9 Months

Vical plans to advance the bivalent vaccine to a Phase 2 trial in 2016 and maintains current financial guidance for 2016

TheStreet Quant Rating: D (Sell)